Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder

Journal of Psychiatry and Neuroscience

Volumn 22, Issue 5, 1997, Pages 332-340

  Shlik, Jakov ^a,c,d   Aluoja, Anu ^a   Vasar, Veiko ^a   Vasar, Eero ^a   Podar, Toomas ^a   Bradwejn, Jacques ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

Blood pressure; Citalopram; Heart rate; Neurosecretory systems; Panic disorder; Serotonin uptake inhibitors; Tetragastrin

Indexed keywords

CITALOPRAM; GROWTH HORMONE; HYDROCORTISONE; LORAZEPAM; SEROTONIN UPTAKE INHIBITOR; TETRAGASTRIN; ZOPICLONE;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; MALE; MENTAL DISEASE; NEUROENDOCRINOLOGY; PANIC; PSYCHOPHARMACOLOGY; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BEHAVIOR; CHOLECYSTOKININ; CITALOPRAM; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; NEUROSECRETORY SYSTEMS; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 0031453608     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sheehan D, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996;57(suppl 10):51-8.
2. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 1991;48:603-10.
3. Bradwejn J, Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Ann N Y Acad Sci 1994;713:273-82.
4. Abelson JL, Nesse RM. Pentagastrin infusions in patients with panic disorders. I. Symptoms and cardiovascular responses. Biol Psychiatry 1994;36:73-83.
5. Van Megen HJGM, Westenberg HGM, den Boer JA, Haigh JRM, Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 1994;114:449-55.
6. Bradwejn J, Koszycki D. Imipramine antagonizes the panicogenic effects of CCK-4 in panic disorder patients. Am J Psychiatry 1994;151:261-3.
7. Van Megen HJGM, Westenberg HGM, den Boer JA, Slaap B, Sheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 1997;129:357-64.
8. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(suppl 1):19-26.
9. Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 1992;6(suppl 5):21-39.
10. Wade AG, Lepola U, Koponen HJ, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-53.
11. World Health Organization. Composite international diagnostic interview (CIDI). Version 1.1. Washington: American Psychiatric Press, Inc.; 1994.
12. Shlik J, Vasar V, Aluoja A, Kingisepp P-H, Jagomägi K, Vasar E, et al. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry 1997;42:206-12.
13. Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education and Welfare; 1976: p. 337-40.
14. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
16. Shear MK, Sholomskas D, Cloitre M. The Multicenter - Panic Anxiety Scale (MC-PAS). Pittsburgh (PA): University of Pittsburg, School of Medicine, Department of Psychiatry; 1992.
17. Spielberger CD, Gorsuch RL, Luchene R. Manual for the statetrait anxiety inventory. Palo Alto (CA): Consulting Psychologists Press; 1970.
18. Derogatis LR, Lipman RS, Covi L. SCL-90. An out patient psychiatric rating scale: preliminary report. Psychopharmacol Bull 1973;9:13-8.
19. Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993;48:119-33.
20. Rex A, Fink H, Marsden CA. Effects of BOC-CCK-4 and L 365,260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology 1994;33:559-65.
21. de Montigny C. Cholecystokinin tetrapeptide induces paniclike attacks in healthy volunteers. Arch Gen Psychiatry 1989;46:511-7.
22. Abelson JL, Nesse RM, Vinik Al. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry 1994;36:84-96.
23. McCann U, Slate SO, Geraci M, Uhde TW. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers. Anxiety 1995:1:258-67.
24. Koszycki D, Zacharko RM, Le Melledo J-M, Joung SN, Bradwejn J. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinintetrapeptide challenge in healthy volunteers. Biol Psychiatry 1996;40:648-55.
25. Biro E, Sarnyai Z, Penke B, Szabo G, Telegdy G. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology 1993;57:340-5.
26. 4 in patients with panic disorder. Eur Neuropsychopharmacol 1996;6:187-94.
27. Brambilla F, Bellodi L, Arancio C, Nobile P, Perna G. Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrinology 1995;20:11-9.
28. Uhde TW, Tancer ME, Rubinow DR, Roskow DB, Boulenger JP, Vittone B, et al. Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 1992;6:101-18.
29. Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, et al. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 1995;152:619-22.
30. Brambilla F, Perna G, Garberi A, Nobile P, Bellodi L. Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology 1995;20:1-9.
31. Kõks S, Vasar E, Soosaar A, Lang A, Volke V, Võikar V, et al. Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur Neuropsychopharmacol. In press.
32. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry 1993;50:306-17.